PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New 'mutation-tracking' blood test could predict breast cancer relapse months in advance

2015-08-26
(Press-News.org) Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.

The test can uncover small numbers of residual cancer cells that have resisted therapy by detecting cancer DNA in the bloodstream.

Researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust were able to track key mutations that cancer accumulates as it develops and spreads, without the need for invasive biopsy procedures.

They hope that by deciphering the DNA code found in blood samples, it should be possible to identify the particularly mutations likely to prove lethal to that patient - and tailor treatment accordingly.

The study, published in the journal Science Translational Medicine, is an important step towards use of 'liquid biopsies' to revolutionise breast cancer care - by changing the way cancer is monitored in the clinic and informing treatment decisions.

The research received funding from a number of organisations including the NIHR Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research (ICR), Breast Cancer Now and Cancer Research UK.

Researchers took tumour and blood samples from 55 breast cancer patients with early-stage disease who had received chemotherapy followed by surgery, and who had potentially been cured of their disease.

By monitoring patients with blood tests taken after surgery and then every six months in follow-up, the researchers were able to predict very accurately who would suffer a relapse.

Women who tested positive for circulating tumour DNA were at 12 times the risk of relapse of those who tested negative, and the return of their cancer was detected an average of 7.9 months before any visible signs emerged.

The researchers used a technique called 'mutation tracking' - developing a digital PCR test that was personalised to the mutations found in an individual patient's cancer - to identify tumour DNA in the bloodstream.

Because the researchers at the ICR and The Royal Marsden were looking for mutations common to many types of breast cancers, they found the test could be applied to all breast cancer subtypes.

The research also showed how genetic mutations build up in the cancer as it develops over time, as the leftover cancer cells grow and spread.

This reinforces the importance of detecting recurrence early so patients can have treatment before the extra mutations emerge and make the disease harder to treat.

Study leader Dr Nicholas Turner, Team Leader in Molecular Oncology at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said:

"We have shown how a simple blood test has the potential to accurately predict which patients will relapse from breast cancer, much earlier than we can currently. We also used blood tests to build a picture of how the cancer was evolving over time, and this information could be invaluable to help doctors select the correct drugs to treat the cancer."

"Ours in the first study to show that these blood tests could be used to predict relapse. It will be some years before the test could potentially be available in hospitals, but we hope to bring this date closer by conducting much larger clinical trials starting next year. There are still challenges in implementing this technology, but digital PCR is relatively cost-effective and the information that it provides could make a real difference to breast cancer patients."

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

"We are moving into an era of personalised medicine for cancer patients. This test could help us stay a step ahead of cancer by monitoring the way it is changing and picking treatments that exploit the weakness of the particular tumour. It is really fantastic that we can get such a comprehensive insight about what is going on in the cancer all over the body, without the need for invasive biopsies.

"Studies like this also give us a better understanding of how cancer changes to evade treatments - knowledge we can use when we are designing the new cancer drugs of the future."

INFORMATION:

Notes to editors

For more information contact Henry French on 020 7153 5380 or henry.french@icr.ac.uk. For enquiries out of hours, please call 07595 963 613.

The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes.

Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden NHS Foundation Trust and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.

The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.

The ICR's mission is to make the discoveries that defeat cancer. For more information visit http://www.icr.ac.uk

The Royal Marsden NHS Foundation Trust

The Royal Marsden opened its doors in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education.

Today, together with its academic partner, The Institute of Cancer Research (ICR), it is the largest and most comprehensive cancer centre in Europe treating over 50,000 NHS and private patients every year. It is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies.

The Royal Marsden, with the ICR, is the only National Institute for Health Research Biomedical Research Centre for Cancer. First awarded the status in 2006, it was re-awarded in 2011. A total of £62 million is being provided over five years, to support pioneering research work, and is being shared out over eight different cancer themes.

The Royal Marsden also provides community services in the London boroughs of Sutton and Merton and in June 2010, along with the ICR, the Trust launched a new academic partnership with Mount Vernon Cancer Centre in Middlesex.

Since 2004, the hospital's charity, The Royal Marsden Cancer Charity, has helped raise over £100 million to build theatres, diagnostic centres, and drug development units.

Prince William became President of The Royal Marsden in 2007, following a long royal connection with the hospital.



ELSE PRESS RELEASES FROM THIS DATE:

DNA sequencing used to identify thousands of fish eggs

2015-08-26
Using DNA sequencing, researchers have accurately painted a clear picture of fish spawning activities in a marine protected area (MPA) and have created a baseline for continuing studies on the effects of climate variability on fish populations. A group of Scripps Institution of Oceanography at UC San Diego researchers led by Ron Burton and Alice Harada collected 260 samples off the Ellen Browning Scripps Memorial Pier over a two-year period and used DNA barcoding to accurately identify over 13,000 fish eggs. This study was also a collaborative effort between the Scripps ...

Self-control saps memory, study says

2015-08-26
DURHAM, N.C. -- You're driving on a busy road and you intend to switch lanes when you suddenly realize that there's a car in your blind spot. You have to put a stop to your lane change -- and quickly. A new study by Duke University researchers suggests that this type of scenario makes a person less likely to remember what halted the action -- for example, the make and model of the car in the blind spot. People and non-human primates excel at "response inhibition." Our sophisticated brains allow us to cancel an action even when it's something engrained, like driving ...

Family farm managers earn less, but gain 'emotional' wealth

2015-08-26
ITHACA, N.Y. - After hours harvesting forage, managing livestock and milking cows, new Cornell University agricultural economic research shows family members who work on the family dairy farm make $22,000 less annually than comparable hired managers, but are handsomely compensated with "socioemotional" wealth. "While $22,000 seems like a large penalty, there are nonfinancial rewards they experience working for the family business," said Loren Tauer, professor at Cornell's Charles H. Dyson School of Applied Economics and Management, who with lead author Jonathan Dressler ...

Colorful potatoes may pack powerful cancer prevention punch

2015-08-26
Compounds found in purple potatoes may help kill colon cancer stem cells and limit the spread of the cancer, according to a team of researchers. Baked purple-fleshed potatoes suppressed the growth of colon cancer tumors in petri dishes and in mice by targeting the cancer's stem cells. Colon cancer is the second leading cause of cancer-related deaths in the U.S. and responsible for more than 50,000 deaths annually, according to the American Cancer Society. Attacking stem cells is an effective way to counter cancer, according to Jairam K.P. Vanamala, associate professor ...

Stiffer breast tissue in obese women promotes tumors

Stiffer breast tissue in obese women promotes tumors
2015-08-26
ITHACA, N.Y. - Women who are obese have a higher risk and a worse prognosis for breast cancer, but the reasons why remain unclear. A Cornell study published this month in Science Translational Medicine explains how obesity changes the consistency of breast tissue in ways that are similar to tumors, thereby promoting disease. The study of mice and women shows obesity leads to a stiffening of a meshwork of material that surrounds fat cells in the breast, called the extracellular matrix, and these biomechanical changes create the right conditions for tumor growth. The findings ...

New survey examines racial and ethnic differences in technology use by millennials

2015-08-26
A new study conducted by the Media Insight Project, a collaboration between the American Press Institute and The Associated Press-NORC Center for Public Affairs Research, found that while the similarities to the rest of their generation are numerous, there are some distinct differences in the way that Hispanic and African American Millennials use technology to access news and information. The source of their information is one area of difference: these young adults are more likely to use YouTube and Instagram for news than Millennials in general, though all groups rely ...

Neurodegenerative disease clogs nuclear pores

2015-08-26
Howard Hughes Medical Institute (HHMI) scientists have discovered how the most common genetic defect in amyotrophic lateral sclerosis kills nerve cells. Their study suggests that the pores that allow molecules into and out of a cell's nucleus get jammed, a finding that could speed the search for other genes that promote this fatal illness. In people who have amyotrophic lateral sclerosis (ALS), the motor neurons that operate the muscles deteriorate. Over time, the disease deprives patients of the ability to walk, swallow, and breathe, and they usually die within three ...

Antimatter catches a wave at SLAC

Antimatter catches a wave at SLAC
2015-08-26
A study led by researchers from the U.S. Department of Energy's (DOE) SLAC National Accelerator Laboratory and the University of California, Los Angeles has demonstrated a new, efficient way to accelerate positrons, the antimatter opposites of electrons. The method may help boost the energy and shrink the size of future linear particle colliders - powerful accelerators that could be used to unravel the properties of nature's fundamental building blocks. The scientists had previously shown that boosting the energy of charged particles by having them "surf" a wave of ionized ...

Capturing cancer

2015-08-26
They're among the most powerful tools for shedding new light on cancer growth and evolution, but mathematical models of the disease for years have faced an either/or stand off. Though models have been developed that capture the spatial aspects of tumors, those models typically don't study genetic changes. Non-spatial models, meanwhile, more accurately portray tumors' evolution, but not their three-dimensional structure. A collaboration between Harvard, Edinburgh, and Johns Hopkins Universities including Martin Nowak, Director of the Program for Evolutionary Dynamics ...

Methanotrophs: Could bacteria help protect our environment?

2015-08-26
New insight into methanotrophs, bacteria that can oxidise methane, may help us develop an array of biotechnological applications that exploit methane and protect our environment from this potent greenhouse gas. Publishing in Nature, scientists led by Newcastle University have provided new understanding of how methanotrophs are able to use large quantities of copper for methane oxidation. They have identified a new family of copper storage proteins called Csp that are present in a range of bacteria. These proteins store metal in a way that has not been seen previously ...

LAST 30 PRESS RELEASES:

A KAIST-Seoul National University Hospital research team develops a computational workflow that predicts metabolites and metabolic pathways associated with somatic mutations in cancers

Bendable energy storage materials by cool science

Inorganic nitrate can help protect patients against kidney damage caused during coronary angiographic procedures

Active social lives help dementia patients, caregivers thrive

New technique measures psilocybin potency of mushrooms

UC Irvine-led research team discovers role of key enzymes that drive cancer mutations

All creatures great and small: Sequencing the blue whale and Etruscan shrew genomes

Sustainable solution for wastewater polluted by dyes used in many industries

Food companies’ sponsorship of children’s sports encourages children to buy their products, Canadian research suggests

USC receives $3.95 million CIRM grant for organoid resource center

New research finds boreal arctic wetlands are producing more methane over time

TLI Investigator Dr. Wei Yan named Editor-in-Chief of the Andrology Journal

New study reveals insights into COVID-19 antibody response durability

Climate change alters the hidden microbial food web in peatlands

Text nudges can increase uptake of COVID-19 boosters– if they play up a sense of ownership of the vaccine

A new study shows how neurochemicals affect fMRI readings

Digital reminders for flu vaccination improves turnout, but not clinical outcomes in older adults

Avatar will not lie... or will it? Scientists investigate how often we change our minds in virtual environments

8-hour time-restricted eating linked to a 91% higher risk of cardiovascular death

Alternative tidal wetlands in plain sight overlooked Blue Carbon superstars

The majority of Americans do not support anti-democratic behavior, even when elected officials do

Genes identified that allow bacteria to thrive despite toxic heavy metal in soil

Scientists’ discovery could reduce dependence on animals for vital anti-blood clot drug

Artificial streams reveal how drought shapes California’s alpine ecosystems

Not in my backyard? Wind turbines have little effect on US property values

The costs of a changing landscape

UMD researchers develop genomic method of monitoring for pesticide resistance

Backyard insect inspires invisibility devices, next gen tech

Americans support democratic norms, elected officials don't

Harnessing hydrogen at life’s origin

[Press-News.org] New 'mutation-tracking' blood test could predict breast cancer relapse months in advance